Stories

This week's research roundup features: High-sensitivity cardiac troponin and the 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guidelines for the evaluation and diagnosis of acute chest pain

Tim Plummer is an operations administrator at Mayo Clinic Laboratories supporting the Division of Anatomic Pathology. He supports his team members by providing them with tools and resources to innovate and succeed. He has worked at Mayo Clinic for over 36 years and is driven by the determination to help people solve problems, help others be happy and successful, and be a part of solutions.

This week's research roundup features: Identification of caveolae-associated protein 4 autoantibodies as a biomarker of immune-mediated rippling muscle disease in adults.

In a recent study, Mayo Clinic researchers developed the first cellular DNA barcoding with a machine-learning approach to reveal previously unknown metastatic behavior of tumor cells. Researchers barcoded the DNA of millions of human ovarian cancer cells and transplanted them in mice, where rare tumor initiating cells and their progenies could be tracked within the primary tumor as well as in every other organ they were spreading into. The entire community of cells generated by a single barcoded cell had identical barcodes. This enabled the tracking of a large number of benign and metastatic clones by sequencing DNA barcodes in tumors and various organs, including blood and ascites. Using the cellular DNA barcoding approach and a newly developed data analysis system, researchers could track clonal growth dynamics in various metastatic sites and trace it back to its ancestral tumor-initiating cell. They used artificial intelligence to tackle the complex data to identify if the clonal metastatic spread is happening peritoneally or through blood routes.

This week's research roundup features: Type 1, type 2 myocardial infarction and non-ischemic myocardial injury-opinion from the front lines

At just 24-years-old Anya Magnuson has survived not just one but two close encounters with death. Focused, determined, and intent on experiencing life to its fullest, Anya never gave up. Nor did the multidisciplinary Mayo Clinic care team who worked tirelessly to heal her.

Todd Walker is a laboratory supervisor for Mayo Clinic Laboratories, Specimen Operations, where he helps lead the department that serves as the gateway between collecting and delivering specimens and getting them processed. Todd credits his diverse, agile team and the impressive global logistics infrastructure that allows them to support the processing of 40,000 specimens in a day.

This week's research roundup features: Gastrointestinal stromal tumors mimicking gynecologic disease: clinicopathological analysis of 20 cases.

This week's research roundup features: Motor-neuron-disease-like phenotype associated with IgLON5 disease.

Working with Mayo Clinic BioPharma Diagnostics clients, Grant Elmquist is engaged in a wide range of activities that span research and science technology, as well as a host of disease states, all with the end goal of enhancing patient care.

This week's research roundup features: Structural Cardiac Abnormalities in Patients with Atrial Fibrillation-Flutter and Myocardial Injury.

Diagnostic tests are a critical part of America’s health infrastructure and helping people live healthier lives. But in a recent op-ed published on RealClearPolicy, William Morice II, M.D., president of Mayo Clinic Laboratories and Matt Sause, president and CEO of Roche Diagnostics North America, explain how the well-intended Protecting Access to Medicare Act of 2014 (PAMA) puts vital diagnostic tests at risk.

Bringing together advanced testing technology, unparalleled expertise, and a patient-focused approach, Mayo Clinic Laboratories’ new high-resolution urine drug testing profile, ADMPU, evaluates for 22 drug classes including alcohol, marijuana, and nicotine, enabling clarity on substance use and precision insights that propel treatment.